Unprecedented Detection of Canine Rabies Antibody - Prostate Specific Antigen Test Solution

Short Description:


Product Detail

Product Tags

Here at QL Biotech, we have ingeniously designed a Prostate Specific Antigen (PSA) Rapid Test Device, which is a testament to our unwavering commitment to healthcare innovation. This powerful device, used in detecting canine rabies antibody, effectively supplements the conventional PSA produced predominantly by prostate glandular and endothelial cells.

SUMMARY

Prostate specific antigen (PSA) is produced by prostate glandular and endothelial cells. It is a single chain glycoprotein with a molecular weight of approximately 34 kDa.1 PSA exists in three major forms circulating in the serum. These forms are free PSA, PSA bound to α1–Antichymotrypsin (PSA‐ACT) and PSA complexed with α2–macroglobulin (PSA‐MG).2 PSA has been detected in various tissues of the male urogenital system but only prostate glandular cells and endothelial cells secrete it. The PSA level in the serum of healthy men is between 0.1 ng/mL and 2.6 ng/mL. It can be elevated in malignant conditions such as prostate cancer, and in benign conditions such as benign prostatic hyperplasia and prostatitis. A PSA level of 4 to 10 ng/mL is considered to be in the “gray‐zone” and above 10 ng/mL is highly indicative of cancer.3 Patients with PSA values between 4‐10 ng/mL should undergo further analysis of the prostate by biopsy. Authorities have begun to explore the possibility of using PSA levels lower than 4.0 ng/mL as the upper limit of normal for screening examinations. By lowering the PSA cutoff from 4 to 3 ng/mL, an increase in cancer detection by 13.2% can be achieved.4 The prostate specific antigen test is the most valuable tool available for the diagnosis of early prostate cancer. Many studies have confirmed that the presence of PSA is the most useful and meaningful tumor marker known for prostate cancer and prostate infection of Benign Prostatic Hyperplasia (BPH).5 The PSA Ultra Prostate Specific Antigen Rapid Test Strip (Whole Blood/Serum/Plasma) utilizes a combination of colloidal gold conjugate and anti‐PSA antibodies to selectively detect all three forms of PSA in whole blood, serum or plasma. The test has a cut‐off value of 4 ng/mL.

 

Product Parameters

Product Name

Prostate Specific Antigen Rapid Test Device

Prostate Specific Antigen Rapid Test Strip

Used for

For professional in vitro diagnostic use only.

Specimen

Whole Blood/Serum/Plasma

Packing

25 tests/box , 1 test/polybag

MOQ

1000 tests

Diverse Coopetation Modes

OEM/ODM


INTERPRETATION OF RESULTS


POSITIVE RESULT: A colored band appears in the control band region (C) and another colored band appears in the T band region.

NEGATIVE RESULT: One colored band appears in the control band region (C). No band appears in the test band region (T).

INVALID RESULT:Control band fails to appear. Results from any test which has not produced a control band at the specified reading time must be discarded. Please review the procedure and repeat with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.

INTERPRETATION OF RESULTS

Sensitivity and Specificity

The PSA Prostate Specific Antigen Rapid Test Device (Whole Blood/Serum/Plasma) has been tested with a leading commercial PSA EIA test using clinical specimens.

Method

EIA

 

Total Results

 

Ultra PSA Rapid Test Device

Results

Positive

Negative

Positive

154

4

158

Negative

2

266

268

Total Results

156

270

426

Relative Sensitivity: 98.7% (97%‐100%)*
Relative Specificity: 98.5% (97.1%‐99.9%)*
Accuracy: 98.6% (97.5%‐99.7%)* *95% Confidence Interval




Surpassing the traditional detection methods, our Prostate Specific Antigen Rapid Test Device utilizes Whole Blood/Serum/Plasma to ensure enhanced accuracy and speed of results. With this tool, veterinarians and researchers can confidently and efficiently identify the presence of canine rabies antibodies. This breakthrough is paramount in the fight against the spread of this deadly disease, enhancing safety measures and aiding in controlling the disease's impact on both animal and human populations. Our state-of-the-art device is meticulously designed to provide rapid results while maintaining the highest level of accuracy. This makes it an invaluable tool for any health professionals working in the field of infectious disease control, dog health management, and epidemiology studies. In our quest to continuously innovate and provide solutions to pressing global health issues, QL Biotech is proud to introduce this revolutionary product that is set to change the face of canine rabies detection. With this solution, we are taking a significant step towards a safer and healthier world for our beloved canines and their human companions.

  • Previous:
  • Next: